[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcranial-magnetic-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcranial-magnetic-stimulation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,54,97,129,157,174,202,234,264,285,313,342,362,390,410,431,460,479,502,526,548],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053678","phase-4-varenicline-and-accelerated-transcranial-magnetic-stimulation-tms-for-quitting-nicotine-use-pilot-study-100053678",false,"NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)","Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use","V-TMS","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Contraindication to D-Cycloserine (including allergy to D-Cycloserine, significant renal impairment or known kidney disease, pregnancy)\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).","ALL","18 Years","65 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS with a single dose of D-Clycloserine to varenicline + sham (inactive) aTMS with a placebo pill to see the effect of enhanced aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active enhanced aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete one day of up to 20 TMS treatments\n* Take a single dose of D-Cycloserine medication on the day of TMS treatment\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],"Nicotine Dependence","Transcranial Magnetic Stimulation","Vaping","Smoking Cessation","Smoking (Tobacco) Addiction",[30,34,35,36,37,38,29,39,40],"Smoking","Nicotine","Adults","Cessation","Varenicline","TMS","D-Cycloserine","RECRUITING","2026-07-09",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":22},"2026-08",{"date":49,"type":22},"2027-12",{"name":51,"class":52},"Massachusetts General Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":77,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":53},"100574927","the-effect-of-non-invasive-brain-stimulation-rtms-on-hand-muscles-in-chronic-stroke-patients-100574927","NCT06765642","The Effect of Non-invasive Brain Stimulation rTMS on Hand Muscles in Chronic Stroke Patients.","Evaluation of 3 Patterned rTMS Stimulation Dosage on Corticospinal Excitability and Motor Learning in Stroke Patients","REALISE","Inclusion criteria:\n\n1. Age \\>=21 years old of any race or gender\n2. First-ever ischemic or hemorrhagic stroke (neuroimaging verified) at least 3 months from stroke onset\n3. Unilateral arm weakness measured by FM-UM scale \\\u003C= 62 out of 66\n4. Inducible rest motor threshold and testing motor threshold recorded from the affected first dorsal interosseous (FDI) muscle from the study subject\n\nExclusion criteria\n\n1. Bilateral strokes (infarcts and\u002For hematoma)\n2. Other co-existent neuromuscular disorders affecting upper extremity motor impairment.\n3. History of medically uncontrolled depression or other neuropsychiatric disorders despite medications either before or after a stroke that may affect the subject's ability to participate in the study.\n4. Uncontrolled hypertension despite medical treatment(s) at the time of randomization, defined as SBP≥185 mmHg or DBP≥110 mmHg (patient can be treated, reassessed and randomized later).\n5. Presence of any MRI\u002FrTMS risk factors including but not limited to:\n\n   1. an electrically, magnetically, or mechanically activated metallic or nonmetallic implant including cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system.\n   2. a non-fixed metallic part in any part of the body, including a previous metallic injury to the eye.\n   3. history of seizure disorder before stroke or seizure after stroke.\n   4. preexisting scalp lesion or bone defect or hemicraniectomy.\n6. Concurrent enrollment in another interventional stroke recovery study.\n7. Concerns that the subject cannot comply with study procedures and visits.\n8. Pregnant individuals","21 Years",{"count":64,"type":22},26,[66],"NA","The study is about using a brain stimulation technique called rTMS (Repetitive Transcranial Magnetic Stimulation) to help improve hand muscles in people who had a stroke. Researchers want to understand how this device can help stroke patients use their hands better.",[69,70,71,72,73,29,74,75,76],"Stroke","Stroke Patients","Arm Weakness as a Consequence of Stroke","Brain Stimulation","Transcranial Magnetic Stimulation Repetitive","Motor Learning","Chronic Stroke Patients","Chronic Stroke Survivors",[78,79,80,81,82,83,84,85,86,87],"stroke","arm weakness","arm weakness as a consequence of stroke","stroke patients","transcranial magnetic stimulation","transcranial magnetic stimulation repetitive","motor learning","chronic stroke","chronic stroke patients","chronic stroke survivors","2026-05-19",{"date":90,"type":45},"2026-05-22",{"date":92,"type":45},"2025-06-09",{"date":94,"type":22},"2027-04-30",{"name":96,"class":52},"Duke University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":19,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":53},"100633734","rtms-for-postoperative-brain-tumor-patients-100633734","NCT07530536","rTMS for Postoperative Brain Tumor Patients","Repetitive Transcranial Magnetic Stimulation for Enhancing Motor Recovery in Postoperative Brain Tumor Patients","Inclusion Criteria:\n\n1. Patients aged 22-65 years old who have undergone surgical resection for a brain tumor.\n2. Patients undergoing any form of prior therapy, other than previous TMS therapy, will be considered.\n3. Patients who present with sustained postoperative motor deficits at 1-2 weeks postoperatively as defined by the presence of British Medical Research Council (MRC) motor scores of 3\u002F5 or less, or a sustained decrement by one point on the MRC score in the affected extremity.\n4. Patients who present within three years of surgery with chronic, persistent motor-functional deficits will be included to demonstrate generalizability of safety and efficacy in neurosurgery patients with chronic deficits.\n5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with any clinical history of seizures.\n2. Patients with implanted devices (e.g., pacemakers, implanted stimulators, intracranial electrodes, cochlear implants).\n3. Patients who have undergone a brain biopsy alone without resection.\n4. Patients with postoperative cognitive deficits as defined by a Mini Mental State Examination score \\\u003C26.\n5. History of bipolar disorder.\n6. Pregnant or breast-feeding individuals.\n7. Active suicidal ideation or plan as assessed by the Columbia Suicide Severity Rating Scale.\n8. History of moderate to severe heart disease.\n9. History of other neurological conditions defined by structural cerebral damage (e.g., stroke, multiple sclerosis, other neurodegenerative diseases, meningoencephalitis)","22 Years",{"count":106,"type":22},6,[66],"When doctors perform surgery to remove brain tumors, the goal is to take out as much of the tumor as possible while keeping the patient's brain functions intact. However, sometimes patients have trouble with movements like walking or using their hands after surgery. One reason for this is unintentional damage to important areas of the brain during the operation. A technique called Transcranial Magnetic Stimulation (TMS) might help patients recover these lost abilities faster.\n\nThe investigators are conducting a study to see if TMS can help patients recover their movement abilities after brain tumor surgery. TMS uses magnetic pulses to stimulate specific parts of the brain. In this study, the investigators will treat six patients with TMS once per day for three days in a row. Three patients with recent movement difficulties one to two weeks after surgery will be recruited for this study; they will also receive physical therapy. An additional three patients with persisting movement difficulties up to three years after tumor surgery will also be recruited for this study, regardless of whether or not they receive physical therapy.\n\nThe investigators will use two standard tests to see how well patients can move before and after the TMS treatment. These tests will help the investigators understand if TMS is making a difference in their recovery.",[110,29,111,112],"Brain Tumors","Motor Deficit","Quality of Life",[114,115,116,117,118,39,119],"Transcranial magnetic stimulation","Brain tumor","Post-operative muscle weakness","Quality of life","Brain tumor surgery","Post-craniotomy","2026-04-10",{"date":122,"type":45},"2026-04-15",{"date":124,"type":22},"2026-06",{"date":126,"type":22},"2028-04",{"name":128,"class":52},"Brian J.Gill",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":53},"100630465","effects-of-the-stimulation-site-of-tsms-with-tms-on-functional-mobility-in-individuals-with-parkinsons-disease-100630465","NCT07488026","Effects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease","Effects of the Stimulation Site of Trans-spinal Magnetic Stimulation Combined With Transcranial Magnetic Stimulation on Functional Mobility in Individuals With Parkinson's Disease","Inclusion Criteria: (i) a clinical diagnosis of Parkinson's disease confirmed by a neurologist; (ii) stable dopaminergic pharmacological treatment for at least three months; (iii) age 40 years or older; (iv) disease stage between 2.5 and 3 on the modified Hoehn and Yahr scale; (v) (v) gait impairment, defined as the occurrence of at least one freezing of gait episode per week.\n\n\\-\n\nExclusion Criteria:\n\n(i) other neurological disorders, orthostatic hypotension, vestibular, musculoskeletal, or visual impairments that could compromise performance on the proposed assessments; (ii) other osteomuscular conditions affecting the lower limbs that interfere with mobility and functional performance; (iii) a Montreal Cognitive Assessment (MoCA) score lower than 21 points; (iv) prior surgical procedures for Parkinson's disease; or (v) contraindications to magnetic stimulation techniques, including a history of seizures or the presence of metallic implants in the neck or spinal region.","40 Years",{"count":21,"type":22},[66],"This randomized clinical trial aims to compare the effects of two different trans-spinal magnetic stimulation (tsMS) application sites, cervical versus thoracic, when combined with repetitive transcranial magnetic stimulation (rTMS), on functional mobility in individuals with Parkinson's disease (PD). Participants diagnosed with PD will be randomized into two intervention groups (rTMS + cervical tsMS or rTMS + thoracic tsMS) and will undergo 10 treatment sessions. Outcomes will include functional mobility, gait speed, motor function, freeing of gait, balance, quality of life, global perceived improvement and adverse events. The study is expected to identify the most effective tsMS application site to enhance mobility and motor outcomes in PD, contributing to the optimization and standardization of tsMS protocols as an adjunct therapy.",[141,142,29,143],"Parkinson's Disease (PD)","Gait Disorders","Spinal Cord Stimulation",[145,146,82,147],"gait disorders","spinal cord stimulation","parkinson's disease","2026-03-18",{"date":150,"type":45},"2026-03-23",{"date":152,"type":45},"2026-01-05",{"date":154,"type":22},"2026-12",{"name":156,"class":52},"Universidade Federal de Pernambuco",{"id":158,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":53},"100604157","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete 5 consecutive days (Monday-Friday, uninterrupted) of TMS treatments\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],[30,34,35,36,37,38,29,39],"NOT_YET_RECRUITING","2026-01-14",{"date":168,"type":45},"2026-01-16",{"date":170,"type":22},"2026-03-15",{"date":172,"type":22},"2027-12-01",{"name":51,"class":52},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100606508","personalized-itbs-in-real-world-clinical-settings-for-schizophrenia-100606508","NCT07176468","Personalized iTBS in Real-World Clinical Settings for Schizophrenia","Efficacy of Personalized iTBS in Real-World Clinical Settings for Alleviating Schizophrenia Symptoms : A Randomized Single-Blind Trial","EPSREAL-SC","Inclusion Criteria:\n\n* Aged 18-60 years, any gender\n* Meets DSM-5 criteria for schizophrenia\n* Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days\n* Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments\n\nExclusion Criteria:\n\n* Active suicidal ideation or behavior\n* Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma)\n* Contraindications to MRI or TMS (e.g., metal implants, pacemakers)\n* Pregnancy or lactation\n* Receipt of TMS or ECT within the past 6 months\n* Judged by investigators to be unsuitable for participation","60 Years",{"count":184,"type":22},40,[66],"This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.\n\nThe main questions it seeks to address are:\n\nDoes the personalized iTBS target TMS protocol improve clinical symptoms in patients with schizophrenia within real-world treatment settings? What neural circuit changes, as assessed by functional MRI, occur following TMS treatment?\n\nParticipants will:\n\nUndergo personalized,personalized iTBS target treatment daily for 2 weeks. Complete baseline and post-treatment assessments, including clinical symptom scales (PANSS, HAMA, HAMD) and neuropsychological tests (MoCA, DST, VFT, Stroop Test, and AVLT).\n\nHave structural and resting-state functional MRI scans before and after treatment.\n\nBe monitored for any treatment-related adverse events.",[188,29],"Schizophrenia",[190,82,191],"schizophrenia","Functional Magnetic Resonance Imaging (fMRI)","2025-12-28",{"date":194,"type":45},"2025-12-30",{"date":196,"type":45},"2025-10-20",{"date":198,"type":22},"2026-09-20",{"name":200,"class":52},"Anhui Medical University",2,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":219,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":53},"100613274","comparison-of-the-efficacy-of-accelerated-intermittent-theta-burst-stimulation-and-accelerated-continuous-theta-burst-stimulation-in-patients-with-treatment-resistant-depression-100613274","NCT07264452","Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression","Inclusion Criteria:\n\n1. 18 to 65 years old\n2. Patients diagnosed with Major Depressive Disorder according to DSM 5 and the severity of their illness\n3. Scoring 7 points or more on the Maudsley staging method\n4. Having depression unresponsive to 2 different antidepressants\n5. No clinical mental retardation\n6. Agree to participate in the study\n7. Hamilton Depression Rating Scale-17 \\[HDRS\\] score of 20 or higher\n8. Montgomery Asberg Depression Rating Scale \\[MADRS\\] score of 20 or above\n9. Being right hand dominant\n10. Having used the same antidepressant at the same dose for the last 4 weeks\n\nExclusion Criteria:\n\n1. Diagnosed with a neurological or metabolic disease that affects cognitive functions (Systemic diseases such as diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic renal failure, Parkinson's disease, multiple sclerosis, polyneuropathy, inflammatory rheumatologic disease and malignancies)\n2. Having a foreign body such as a pacemaker, intracranial implant that can magnetically interact\n3. Hearing and visual impairments that prevent communication\n4. Unstable or acute medical conditions\n5. Pregnancy or breastfeeding\n6. Having a primary psychiatric disorder other than major depressive disorder\n7. Being diagnosed with severe MDD with psychotic features",true,{"count":210,"type":22},60,[66],"In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing. The aim of this study was to examine the effectiveness of accelerated unilateral application of two different forms of theta burst stimulation (TBU), a variation of repetitive TMU (rTMS)-intermittent TBU (iTBU) and continuous TBU (cTBU)-in TDD patients. The study aimed to compare the advantages of iTBU and cTBU protocols on depression, suicidal thoughts, anxiety levels, sleep disturbances, cognitive performance, and overall functioning following a two-week intensive treatment period and a 12-week follow-up period.",[214,29,215,216,217,218],"Treatment Resistant Depression (TRD)","Accelerated Protocol","Intermittent Theta Burst Stimulation","Continuous Theta Burst Stimulation","Unilateral rTMS",[214,29,220,221,222,218,223,224],"Accelerated protocol","intermittent theta burst stimulation","Continuous theta burst stimulation","unipolar major depressive disorder","non-invasive brain stimulation","2025-12-02",{"date":227,"type":45},"2025-12-04",{"date":229,"type":45},"2025-11-15",{"date":231,"type":22},"2027-01-15",{"name":233,"class":52},"Ataturk University",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":250,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":263},"100567514","advantage-of-cerebellar-transcranial-magnetic-stimulation-in-alzheimers-diseases-act-ad-100567514","NCT06669182","Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）","Effects of Cerebellar Transcranial Magnetic Stimulation on Patients With Alzheimer's Disease：A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 50-85 years old\n2. Meet the core clinical criteria of NIA-AA for possible Alzheimer's disease dementia, and PET or cerebrospinal fluid markers show elevated p-tau and decreased A β (1-42)\n3. MMSE score ranges from 18-26 points; CDR score 0.5-1 points\n4. The patient has received treatment with acetylcholinesterase inhibitors (AChEI), NMDA receptor antagonists, or mannequine therapy, and the current dosing regimen has remained stable for the 12 weeks prior to baseline assessment\n5. At least one adult caregiver\n6. The patient or legal guardian voluntarily signs the informed consent form\n\nExclusion Criteria:\n\n1. Neurodegenerative disorders other than AD.\n2. Significant intracranial focal or vascular pathology seen on brain MRI scan\n3. History of seizure (with the exception of febrile seizures in childhood)\n4. Any of the following psychotic disorders (DSM IV-TR criteria):\n\n   * Major depressive disorder (current)\n   * Schizophrenia\n   * Other psychotic disorders, bipolar disorder, or substance related disorders (within the past 5 years)\n5. GDS score ≥ 8 points in baseline assessment\n6. Cerebrovascular disease, severe infection, malignant tumor, or severe dysfunction of organs such as heart, liver, and kidney.\n7. Pregnant or lactating women\n8. Contraindications for TMS or MRI, metal or implanted devices in the body (such as pacemakers, deep brain stimulators).\n9. Participate in AD related clinical trials within 6 months prior to research registration","50 Years","85 Years",{"count":244,"type":22},100,[66],"Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) in participants with mild Alzheimer's disease on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 3 months of treatment in the Core Study. This project aims to provide a valid treatment to improve the cognitive function and quality of life for those with Alzheimer's disease.",[248,29,249],"Alzheimer Disease","Cerebellum",[114,251,252,253,254],"Intermittent theta burst stimulation","Cerebellar cognitive reserve","Default mode network","Alzheimer's disease","2025-11-18",{"date":257,"type":45},"2025-11-24",{"date":259,"type":45},"2025-01-07",{"date":120,"type":22},{"name":262,"class":52},"Xijing Hospital",4,{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":242,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":53},"100454070","effect-of-theta-burst-transcranial-magnetic-stimulation-tbs-for-freezing-of-gait-100454070","NCT05192759","Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait","Inclusion Criteria:\n\n1. diagnosis of FOG with expertise in movement disorders.\n2. the score of item 3 of the FOG questionnaire ≥1.\n3. ongoing treatment with a stable dose of any medication for 2 months.\n4. 40 years of age or older.\n\nExclusion Criteria:\n\n1. a history of addiction, psychiatric disorders, or neurological diseases other than PD.\n2. focal brain lesions on T1-\u002FT2-weighted fluid-attenuated inversion recovery images.\n3. anti-PD medication adjustments during rTMS treatment.\n4. history of substance abuse within the past 6 months.\n5. nonremovable metal objects in or around the head.\n6. previously received rTMS treatment.\n7. prior history of seizure or history in first-degree relatives.",{"count":184,"type":22},[66],"To investigate the treatment effect of Theta-burst Transcranial Magnetic Stimulation (TBS) on patients with freezing of gait (FOG) and the underlying neural mechanism.",[29,274],"Freezing of Gait",[29,276],"Freezing of gait","2025-11-17",{"date":279,"type":45},"2025-11-19",{"date":281,"type":45},"2021-11-22",{"date":283,"type":22},"2028-12-30",{"name":200,"class":52},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":53},"100560536","deep-tms-of-neural-circuits-associated-with-stimulant-use-disorder-100560536","NCT06578429","Deep TMS of Neural Circuits Associated With Stimulant Use Disorder","Deep TMS Neuromodulation of Neural Circuits Associated With Stimulant Use Disorder","Inclusion:\n\n* Must be within the age range of 25-75.\n* Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for moderate to severe MUD (≥4 diagnostic symptoms).\n* Participants must be able to obtain a Motor Threshold (MT), which will be determined during the screening process.\n* Participants must have an adequately stable condition and environment to enable attendance at scheduled clinic visits.\n* Participants must be able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participation in study procedures in English.\n* If participants are on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase.\n* Participants must be fluent in English\n\nExclusion criteria:\n\n* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device\u002Fobject in the head and body within 30 cm of the treatment coil.\n* General medical condition, disease, or neurological disorder that interferes with the assessments or participation.\n* Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.\n* Current substance abuse as determined by positive toxicology screen\n* Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder.\n* A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.\n* Severe impediment to vision, hearing and\u002For hand movement, as this is likely to interfere with the ability to follow study protocols.\n* Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).\n* Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold.\n* Acute or unstable chronic illness.\n* Current or lifetime history of bipolar disorder or psychosis.\n* Participation in another concurrent intervention-based clinical trial.","25 Years","75 Years",{"count":21,"type":22},[66],"This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with a methamphetamine use disorder (MUD).",[298,29],"Methamphetamine Use Disorder",[300,301,302,303],"Veterans","Deep Transcranial Magnetic Stimulation (dTMS)","Neuroimaging","Relapse","2025-09-10",{"date":306,"type":45},"2025-09-12",{"date":308,"type":45},"2025-03-15",{"date":310,"type":22},"2026-12-31",{"name":312,"class":52},"Stanford University",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":53},"100567360","phase-1-effects-of-low-intensity-transcranial-magnetic-stimulation-on-major-depressive-disorder-and-on-5-hydroxyindoleacetic-acid-and-brain-derived-neurotrophic-factor-levels-100567360","NCT06667180","Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels","Inclusion Criteria:\n\n* Age between 18 and 60 years.\n* Both sexes.\n* Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes).\n* Those who continue with their respective treatment and attend follow-up consultations at the health facility.\n* Those who do not have a history of epilepsy, schizophrenia, neurosurgeries.\n* Those who do not have metal plates anywhere in the skull, neck, chest and shoulder.\n* Those who do not use pacemakers.\n* Those who do not take hormone substitutes.\n* Those who agree to participate in the research.\n\nExclusion Criteria:\n\n* Those who are pregnant.",{"count":184,"type":22},[321,322],"PHASE1","PHASE2","The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder. Final metabolites of serotonin such as 5-HIAA and growth factors such as BDNF will also be studied before starting the intervention and at the end to check if there is a significant change in their concentration. Likewise, its safety will be evaluated by monitoring the symptoms that they present at the end of the intervention and one month later. The main questions that are intended to be answered are:\n\n* Does low-intensity TMS reduce depressive symptoms in patients with MDD?\n* Does low-intensity TMS significantly change the initial and final concentrations of 5-HIAA and BDNF?\n* What adverse effects might patients who are exposed to low-intensity TMS experience? The researchers will compare low-intensity and accelerated TMS with sham TMS to see if low-intensity TMS works to treat MDD.\n\nParticipants:\n\n* Will undergo an initial clinical assessment to confirm the disorder, comorbidities, and general health status.\n* A 5 mL blood sample will be taken before starting the intervention.\n* Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 milliTesla (mT) and frequency of 50 Hz in theta bursts. Symptoms will be monitored daily.\n* A 5 mL blood sample will be taken at the end of the intervention and general health status clinimetrics will be reapplied.",[325,29,326],"Depression - Major Depressive Disorder","Placebo",[328,329,330,331,332],"accelerated low-intensity transcranial magnetic stimulation","Major depressive disorder","depression","brain-derived neurotrophic factor","5-hydroxyindoleacetic acid","2025-05-05",{"date":335,"type":45},"2025-05-08",{"date":337,"type":45},"2024-10-28",{"date":339,"type":22},"2025-08-26",{"name":341,"class":52},"Universidad de Guanajuato",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":53},"100580093","long-term-efficacy-and-safety-of-tms-targeting-cerebellum-to-treat-dre-100580093","NCT06832813","Long Term Efficacy and Safety of TMS Targeting Cerebellum to Treat DRE","Long Term Efficacy and Safety of Transcranial Magnetic Stimulation Targeting Cerebellum to Treat Drug-resistant Epilepsy During Enhanced and Maintenance Phase","Inclusion Criteria:\n\n1. Age 18-65 years old，\n2. Participants who are diagnosed as drug- resistant epilepsy,\n3. Participants who has a history of DRE ≥2 years before enrollment，\n4. Participants who has a seizure frequency of ≥2 seizures every month within 3 months before enrollment,\n5. Participants and their families are aware of this study and sign informed consent.\n\nExclusion Criteria:\n\n1. Participants who are in status epilepticus,\n2. Participants who are complicated with serious infection, cerebrovascular disease, malignant tumor and other nervous system diseases, with serious dysfunction of heart, liver, kidney and other organs, and with psychiatric disorders,\n3. Participants plan invasive therapy, such as operation,\n4. Participants who are in pregnancy or lactating,\n5. Patients cannot tolerate repeated transcranial magnetic stimulation, or have contraindications of repeated transcranial magnetic stimulation.",{"count":244,"type":22},[66],"This study aims to observe the long term efficacy and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-resistant Epilepsy during enhanced and maintenance phase，in order to provide a new treatment for long-term control of drug-resistant epilepsy and improve the quality of life of those patients. A total of 100 patients with DRE will undergo cTBS treatment by precise navigation to bilateral cerebellar dentate nuclei. The frequency and clinical feature of seizures, scalp EEG，clinical score, MOCA，MMSE，and QOLIE-31 were ssessed at baseline, after 2 weeks of enhanced phase，8 weeks of consolidate phase, and 8 weeks of maintenance phase.",[353,29],"Drug-resistant Epilepsy","2025-03-30",{"date":356,"type":45},"2025-04-03",{"date":358,"type":22},"2025-03-28",{"date":360,"type":22},"2027-03-27",{"name":262,"class":52},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":208,"sex":369,"minAge":18,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":53},"100581823","evaluating-combined-electromagnetic-stimulation-for-enhanced-physical-and-psychological-recovery-in-athletes-with-doms-100581823","NCT06855316","Evaluating Combined Electromagnetic Stimulation for Enhanced Physical and Psychological Recovery in Athletes with DOMS","Evaluating Combined Electromagnetic Stimulation for Enhanced Physical and Psychological Recovery in Athletes with DOMS: a Randomized Controlled Study","Inclusion Criteria:\n\n1. be male,\n2. aged between 18 and 35 years\n3. engage in regular exercise at least three times per week for a minimum of one year\n4. have no hypersensitivity to the areas designated for peripheral stimulation\n5. be free from chronic conditions incompatible with exercise performance\n6. have no recent musculoskeletal injuries to the lower limbs within the past six months,\n7. be non-smokers\n8. possess the cognitive capacity to understand the study's objectives and procedures.\n\nExclusion Criteria:\n\n\\-","MALE","35 Years",{"count":372,"type":22},48,[66],"This randomized controlled trial explores the impact of a combined transcranial and peripheral electromagnetic stimulation over the potential correlation between psychological well-being and recovery outcomes of young athletes experiencing Delayed Onset Muscle Soreness.",[376,29],"Recovery, Psychological",[378,379,380],"transcraneal magnetic stimulation","delay onset muscle soreness","psychological profile","2025-02-26",{"date":383,"type":45},"2025-03-03",{"date":385,"type":22},"2025-02-24",{"date":387,"type":22},"2025-03-07",{"name":389,"class":52},"Sierra Varona SL",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":53},"100580431","precision-transcranial-magnetic-stimulation-for-depression-based-on-orbital-frontal-cortex-habenula-circuitry-100580431","NCT06837207","Precision Transcranial Magnetic Stimulation for Depression Based on Orbital Frontal Cortex-habenula Circuitry","Safety and Efficacy Study of Precise Transcranial Magnetic Stimulation for Depression Based on Individualized Functional Connectivity Localization of Orbital Frontal Cortex-habenula","Inclusion Criteria:\n\n* Gender is not limited, age 18～60 years old;\n* Comply with the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) of the United States of America;\n* Hamilton rating scale for depression (HAMD) 17-item score ≥ 18;\n* The medication\u002Fpsychotherapy received by the subject prior to the start of the study remained stable for at least 4 weeks .\n\nExclusion Criteria:\n\n* History of serious somatic diseases or diseases that may affect the central nervous system (e.g., tumors, syphilis, etc.);\n* Neurological disorders or risk of seizures, such as previous craniosynostosis, head trauma, alcoholism, abnormal electroencephalograms, MRI evidence of structural abnormalities in the brain, or family history of epilepsy;\n* Patients with bipolar disorder and depression due to other psychiatric disorders (e.g., psychoactive and non-dependent substances);\n* Contraindications to MRI scanning or transcranial magnetic stimulation therapy, such as metal or electronic devices placed in the body (intracranial metal foreign bodies, cochlear implants, pacemakers and stents and other metal foreign bodies), space phobia;\n* People with psychotic symptoms requiring joint application of antipsychotic drugs;\n* Those with high risk of suicide, or those who have already committed suicide or serious self-injury behavior requiring urgent intervention;\n* Those who are pregnant, breastfeeding or planning to become pregnant during the trial;\n* Other conditions judged by the investigator to be unsuitable as research subjects.",{"count":21,"type":22},[66],"Thirty depressed patients will be recruited to select individualized transcranial magnetic stimulation targets based on individual orbital frontal cortex and habenula functional activity connectivity for 10 or 20 treatments to assess the efficacy and safety of this intervention",[401,29],"Depression","2025-02-16",{"date":404,"type":45},"2025-02-20",{"date":406,"type":22},"2025-03-01",{"date":408,"type":22},"2026-03-01",{"name":262,"class":52},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":417,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":53},"100509485","individualized-rtms-for-motor-recovery-in-stroke-patients-100509485","NCT05914038","Individualized rTMS for Motor Recovery in Stroke Patients","Efficacy of Individualized Repetitive Transcranial Magnetic Stimulation Based on Cortical Laterality for Motor Recovery in Stroke Patients","Inclusion Criteria:\n\n1. Unilateral ischemic or hemorrhagic stroke\n2. Stroke within 3 months\n3. Medical Research Council Scale for Muscle Strength in upper limb ≤ 3\n4. No previous stroke, seizure, dementia, Parkinson's disease or other degenerative neurological diseases.\n5. Patient could sit over 15 minutes\n6. Age over 20\n\nExclusion Criteria:\n\n1. Previous stroke, traumatic brain injury, brain tumor\n2. With central nervous system disease (spinal cord injury, Parkinson's disease)\n3. Any contraindication to rTMS (seizure, alcoholism, metal implant, pacemaker)\n4. Patients unable to cooperate the treatment\n5. Pregnancy\n6. Depression","20 Years",{"count":184,"type":22},[66],"This study aimed to aim to investigate the efficacy of individualized rTMS according to lateralization index on motor recovery and cortical excitability in subacute stroke patients.",[69,29],"2024-10-16",{"date":424,"type":45},"2024-10-18",{"date":426,"type":45},"2023-10-13",{"date":428,"type":22},"2027-05-20",{"name":430,"class":52},"National Taiwan University Hospital",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":444,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":53},"100562146","evaluation-of-the-efficacy-of-transcranial-magnetic-stimulation-on-resistant-auditory-hallucinations-in-schizophrenia-100562146","NCT06599372","Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia","Treatment of Resistant Auditory Hallucinations in Schizophrenia by Repetitive Transcranial Magnetic Stimulation. Naturalistic Study","HRRENAT","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patient diagnosed with schizophrenia according to DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorder V5, 2013)\n* Presence of auditory hallucinations: Resistant auditory hallucinations: resistance to treatment with 2 different well-conducted antipsychotics.\n* Patient agreeing to participate in the study and having signed an informed consent\n* Patient with French language skills\n* Affiliation to a social security system\n* Women of childbearing age must be on contraception and have a negative pregnancy test (βHCG)\n\nExclusion Criteria:\n\n* Have a contraindication to MST: intracranial foreign body, unstabilized epilepsy, cochlear implant\n* Presence of an unstabilized medical condition\n* Pregnant woman (Women of childbearing age without effective contraception)\n* Current or less than one month old engagement in another research protocol\n* A person who is subject to a safeguard of justice measure\n* An adult under curatorship\n* Minor patients with mental health problems\n* Pregnant or breastfeeding women\n* A person in a social fragility (Persons deprived of liberty by a judicial or administrative decision, hospitalized persons)\n* Persons incapable or unable to give consent",{"count":21,"type":22},[66],"This open naturalistic study aims to evaluate the efficacy of rTMS in routine practice on auditory resistant hallucinations (AHR) of patients with schizophrenia. To this end, two stimulation methods will be offered to patients: the rTMS stimulation method and the cTBS stimulation method.We principally use the AHRS scale to evaluate the effectiveness of rTMS on RAH in patients with schizophrenia. Our main hypothesis is that rTMS used under naturalistic conditions, in addition to antipsychotics, would allow a relative improvement of resistant auditory hallucinations assessed by the AHRS scale between baseline and end of treatment in patients with schizophrenia.",[188,29,443],"Hallucinations, Verbal Auditory",[445,446,190,39,114,447,448,449,450],"hallucinations","resistant auditory hallucinations","TBS","Theta burst stimulation","a improvement","real-life conditions","2024-09-12",{"date":453,"type":45},"2024-09-19",{"date":455,"type":45},"2022-07-11",{"date":457,"type":22},"2027-11",{"name":459,"class":52},"Dominique JANUEL",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":417,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":53},"100486408","theta-burst-stimulation-for-motor-recovery-100486408","NCT05613686","Theta Burst Stimulation for Motor Recovery","Comparative Efficacy of Different Doses of Theta Burst Stimulation for Motor Recovery in Stroke Patients","Inclusion Criteria:\n\n* 1.Unilateral ischemic or hemorrhagic stroke\n* 2.Stroke within 3 months\n* 3.Medical Research Council Scale for Muscle Strength in upper limb ≤ 3\n* 4.No previous stroke, seizure, dementia, Parkinson's disease or other degenerative neurological diseases.\n* 5.Patient could sit over 15 minutes\n* 6.Age over 20\n\nExclusion Criteria:\n\n* 1.Previous stroke, traumatic brain injury, brain tumor\n* 2.With central nervous system disease (spinal cord injury, Parkinson's disease)\n* 3.Any contraindication to rTMS (seizure, alcoholism, metal implant, pacemaker)\n* 4.Patients unable to cooperate the treatment\n* 5.Pregnancy\n* 6.Depression",{"count":210,"type":22},[66],"Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. This study will compare efficacy of different doses iTBS in combination with inhibitory rTMS on motor recovery and cortical excitability in subacute stroke patients.",[29],"2024-08-16",{"date":473,"type":45},"2024-08-19",{"date":475,"type":45},"2022-10-29",{"date":477,"type":22},"2024-10-29",{"name":430,"class":52},{"id":480,"slug":481,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":53},"100557813","an-open-label-study-on-the-clinical-efficacy-of-rtms-intervention-in-pd-100557813","NCT06542991","An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD","Inclusion Criteria:\n\n1. Age ≥40 years old\n2. Meet Movement Disorder Society standards;\n3. Have no history of drug adjustment within 4 weeks before and during treatment;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4\n5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Head MRI\u002FCT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.",{"count":486,"type":22},20,[66],"To demonstrate that intervention targeting the supplementary motor area (SMA) using precise navigation positioning can effectively improve motor symptoms in patients with Parkinson's disease.",[29,490,491],"Parkinson Disease","Supplementary Motor Area",[29,490,493],"Supplementary motor area","2024-08-03",{"date":496,"type":45},"2024-08-07",{"date":498,"type":22},"2024-09-01",{"date":500,"type":22},"2025-03-31",{"name":200,"class":52},{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":53},"100453627","effects-of-individualized-rtms-in-doc-patients-100453627","NCT05187000","Effects of Individualized rTMS in DOC Patients","Effect of Individualized Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Disorder of Consciousness","Inclusion Criteria:\n\n1. acquired brain injuries less than 1 year and more than 28 days in DOC;\n2. clinical diagnosis of DOC Disease;\n3. no medical history of neuropsychiatric diseases;\n4. no contraindications for rTMS or EEG, no sedatives in use or other drugs that might interfere with brain stimulation, such as Na+ or Ca2+ channel blockers or NMDA receptor antagonists;\n5. stable state of disease and vital signs;\n6. the families of the patients volunteered the patient to participate in the study and provided signed informed consent;\n7. the integrity of the individualized stimulation target cortex are verified by MRI.\n\nExclusion Criteria:\n\n1. patients in other non-invasive or invasive neuroregulation trials;\n2. motor evoked potential (MEP) in M1 region cannot be induced by TMS pulse;\n3. uncontrolled epilepsy, seizure within 4 weeks before enrollment;\n4. metallic implant in the skull, pacemaker, craniotomy under the stimulated site, implanted brain device.","70 Years",{"count":21,"type":22},[66],"Background: Disorder of consciousness(DOC) is a series of arousal and cognitive disorders secondary to the most severe brain injury. Once a patient is diagnosed with a DOC, a poor prognosis is assumed and the rehabilitation for whom is greatly limited. Therefore, the treatment of DOC poses extraordinary challenges. Various treatments protocols have been reported of successful in promoting rehabilitation of DOC patients. Repetitive transcranial magnetic stimulation(rTMS), as a non-invasive brain stimulation technique, has shown potentials for consciousness rehabilitation of DOC patients as it is effective in regulating the central nervous system.\n\nMethods and design: This protocol is a double-blind randomized sham-controlled crossover trial. Totally 30 participants will be randomly assigned to either group 1 or group 2 in a 1:1 ratio, with 15 patients in each group. Each patient will received 20 sessions, in which 10 sessions will be active and 10 will be sham, separated by 10-days washout period. The active-rTMS will include 10 Hz rTMS over the individual-targeted area on each participants. Primary and secondary evaluating indicators will be performed at each baseline and after rTMS treatment. Primary outcome will be determined as behavioral response to treatment as measured using the Coma Recovery Scale - Revised (CRS-R). Resting-state high-density EEG will be also recorded to investigate the neurophysiological correlates by rTMS.\n\nDiscussion:This study will contribute to define the role of rTMS for the treatment of DOC patients and characterise the neural correlates of its action. The investigators proposed a method of individualized target selection for DOC patients based on the existing gold standard CRS-R score and MRI, and used a cross randomized controlled trial to verify the role of rTMS in DOC treatment.",[514,29],"Disorder of Consciousness",[514,516,517],"repetitive transcranial magnetic stimulation","randomized control trial","2024-07-25",{"date":520,"type":45},"2024-07-26",{"date":522,"type":45},"2021-07-05",{"date":500,"type":22},{"name":525,"class":52},"Qiuyou Xie",{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":17,"minAge":417,"maxAge":242,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":4},"100553152","a-pilot-study-of-repetitive-transcranial-magnetic-stimulation-100553152","NCT06482372","A Pilot Study of Repetitive Transcranial Magnetic Stimulation","Effects of Repetitive Transcranial Magnetic Stimulation Combined With Mirror Therapy on Upper Limb Function in Patients With Stroke: a Pilot Study","Inclusion Criteria:\n\n* at least 1 month after stroke\n* manual muscle strength \\\u003C 5\n\nExclusion Criteria:\n\n* history of epilepsy\n* has other central nervous system diseases\n* has electric medication pump\n* has implant at inner ear",{"count":534,"type":22},69,[66],"Stroke patients often have long-term upper limb dysfunction. Currently, there is still no specific clinical treatment for nerve damage. After acute treatments of stroke, patients' motor ability can only improve by spontaneous recovery of brain and rehabilitation treatment.\n\nTranscranial magnetic stimulation uses a magnetic field pulse generated by a coil outside the skull to pass through the skull. It uses the principle that magnetic electricity can generate currents, which activates nearby brain areas or changing the relationship between the left and right brains. Transcranial magnetic stimulation is a non-invasive, safe treatment.\n\nMirror therapy is an emerging rehabilitation method in recent years. As mirror therapy, therapists ask the patient to place the affected hand behind the mirror while looking at the image reflected by the unaffected upper limb. During mirror therapy, patients have to perform upper limb activities and imagine that the affected upper limb is performing the same action.\n\nAs mentioned above, transcranial magnetic stimulation and mirror therapy improve the recovery of stroke patients by two different ways. Currently, there are no studies that combine these two treatments. Therefore, our study hopes to initially explore the efficacy of transcranial magnetic stimulation and the efficacy of transcranial magnetic stimulation combined with mirror therapy.",[69,538,29],"Mirror Therapy","2024-06-28",{"date":541,"type":45},"2024-07-01",{"date":543,"type":22},"2024-10-01",{"date":545,"type":22},"2027-06-30",{"name":547,"class":52},"Cheng-Hsin General Hospital",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":564,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":53},"100534679","high-definition-transcranial-direct-current-stimulation-hd-tdcs-for-refractory-epilepsy-100534679","NCT06241963","High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy","The Efficacy, Safety and Mechanism of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Refractory Epilepsy","Inclusion Criteria:\n\n* Clinical diagnosis of refractory epilepsy\n* Right-handed and aged 18-50 years old and primary school education or above;\n* No major neurological or mental illness, no head injury, alcohol dependence or drug dependence;\n* During the experiment, the subjects did not smoke, drink, get sick and take psychotropic drugs, and there were no major life events that caused mood changes.\n\nExclusion Criteria:\n\n* organic brain injury, neurological diseases or serious physical diseases;\n* Have a history of substance abuse and drug dependence, or have used antipsychotic drugs in the past three months, and have serious suicidal tendencies;\n* There are contraindications for MRI or EEG or transcranial magnetic stimulation.",{"count":556,"type":22},90,[66],"To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.",[560,561,562,563,29],"Transcranial Direct Current Stimulation","EEG","Functional Magnetic Resonance Imaging","Refractory Epilepsy",[563,562,561,114],"2024-02-15",{"date":567,"type":45},"2024-02-20",{"date":569,"type":22},"2024-02-12",{"date":571,"type":22},"2026-06-30",{"name":200,"class":52}]